Obesity Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

16/feb/2018 12:57:57 pbi Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Obesity is the medical condition occurs due to the excessive or abnormal accumulation of fat inside the body. Obesity is measured with respect to Basal Metabolic Index (BMI). According to world health organization, more than 30 BMI is considered as the obese. Obesity may lead to osteoarthritis, cardiovascular diseases, diabetes, and various types of cancer. The risk factors for obesity include lack of physical exercise, excessive food intake, endocrine disorders, genetic inheritance, and due to some medications.  obesity treatment reduces the body mass either by an increase in calorie consumption or by the decrease in craving.

 Increase in the prevalence of obese population around the globe, increase in R&D activities for the innovation of new treatment, change in lifestyle such as food habits, and genetic inheritance is the major factors anticipated fuel the obesity treatment market over the forecast period. Moreover, increase in awareness about obesity treatment, huge pipeline products available for the obesity treatment, and government initiations for increasing awareness about chronic nature of obesity are propelling the obesity treatment market. However, high cost for R&D activities, alternative treatment for the obesity, adverse effects associated with the treatment, and stringent regulatory guidelines might hinder the growth of Obesity Treatment Market


A sample of this report is available upon request @





Global obesity treatment market segmented on the basis of drug type, mechanism of action, distribution mode, route of administration, and distribution channel


Based on the medicine type, obesity treatment market segmented into the following:

·         Centrally acting obesity medicines

·         Peripherally acting obesity medicines


Based on the mechanism of action, obesity treatment market segmented into the following:

·         Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs)

·         Serotonin reuptake inhibitors

·         Sympathomimetic-GABA receptor agonists

·         Sympathomimetics

·         Others


Based on the distribution mode, obesity treatment market segmented into the following:

·         Over-the-counter medicines

·         Prescription medicines


Based on the route of administration, obesity treatment market segmented into the following:

·         Oral

·         Injectables


Based on the distribution channel, obesity treatment market segmented into the following:

·         Hospital pharmacies

·         Retail pharmacies

·         Online pharmacies


To view TOC of this report is available upon request @






Global obesity treatment market expected to grow at a significant CAGR owing to increase in the R&D activities for the innovation of new products and presence of various pipeline products for the treatment of obesity. Increase in the prevalence of obese population fuelling the obesity treatment market growth. According to World Health Organization 2014, more than 39% of adults (600 Mn adults) adults and 42 Mn children were obese. In addition, entry of generic products due to patent expiry of blockbuster treatment also driving the revenue of obesity treatment. For instance, in March 2017, Novo Nordisk has received European Commission marketing authorization approval of Saxenda an injectable obesity drug and launched the same in India market in 2017.


Need more information about this report @





Geographically, obesity treatment market segmented into North America, Europe, Middle East and Africa, Latin America, and Asia Pacific. North America has a significant share in global obesity treatment market owing to increase in the R&D activities for the innovation of newer products, rise in prevalence of obese population majorly in U.S. (according to Centers for Disease Control and Prevention 2014, about 36.5% adults were obese in U.S.). In Europe, the obesity prevalence is growing (according to World Health Organization, in Europe more than 30% people were obese) due to changes in lifestyle, food habits, and hectic work schedules. Moreover, launching of new products into the Europe market, the rise in healthcare expenditure, increase in R&D activities, and awareness about the causes of obesity are anticipated to boost the obesity treatment market. However, Asia Pacific is an emerging market owing to increase in the medical tourism majorly in India and China, a rise in adult population, increase in per capita income, and diversification of business into Asia Pacific region by market players.



Some of the players in  obesity treatmet market are Boehringer Ingelheim GmbH (Germany), Takeda Pharmaceuticals co. Ltd. (Japan), Novo Nordisk A/S (Denmark), GlaxoSmithKline Plc (U.K.), AstraZeneca Plc (U.K.), F. Hoffmann La Roche Ltd. (Switzerland), Pfizer, Inc. (U.S.), Gubra (Denmark), Orexigen Therapeutics Inc. (U.S.), and Eisai Co. Ltd. (Japan) to name a few.


Get access to full summary @


blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl